Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  COMPANY NEWS
Company News      
Gland Pharma Ltd.
Change Company   
BSE Code 543245
ISIN Demat INE068V01023
Book Value 556.82
NSE Code GLAND
Dividend Yield % 1.13
Market Cap 291569.36
P/E 26.44
EPS 66.94
Face Value 1  
12-Dec-2024 Gland Pharma gets USFDA’s approval for Phytonadio...
12-Dec-2024 Gland Pharma shines on getting USFDA’s approval f...
03-Dec-2024 Gland Pharma gets USFDA’s nod for Latanoprost Oph...
03-Dec-2024 Gland Pharma informs about analyst meet
03-Dec-2024 Gland Pharma informs about press release
03-Dec-2024 Gland Pharma jumps on getting USFDA’s nod for Lat...
08-Nov-2024 Gland Pharma informs about analyst meet
05-Nov-2024 Gland Pharma reports 16% fall in Q2 consolidated ...
05-Nov-2024 Gland Pharma zooms despite reporting 16% fall in ...
05-Aug-2024 Gland Pharma falls after USFDA concludes inspecti...
02-Aug-2024 USFDA conducts inspection at Gland Pharma’s Pasha...
25-Jul-2024 USFDA concludes inspection at Gland Pharma’s Hyde...
24-Jul-2024 Gland Pharma jumps on getting USFDA’s tentative a...
23-Jul-2024 Gland Pharma gets USFDA’s tentative approval for ...
26-Jun-2024 Gland Pharma informs about disclosure
Page 1 of 2
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA
Publishing of investor charter information | Annexure A – Investor charter of brokers |
Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.